

Immunoregulatory nanomedicine for respiratory infections

In the format provided by the
authors and unedited

Supplementary information

Immunoregulatory nanomedicine for respiratory infections

Yafang Xiao^{1,#}, Yuanyu Huang^{2,#,}, Maobin Xie^{1,#}, Minghui Yang², Ying Tao¹, Lu Liu^{6,7}, Jiasheng Wu¹ Guoxi Xie¹, Jinbao Liu³, Tao Xu^{1,4,5,7}, Weisheng Guo^{1,8,*}, Xing-Jie Liang^{1,6,7,*}*

¹Department of Minimally Invasive Interventional Radiology, the State Key Laboratory of Respiratory Disease, School of Biomedical Engineering & The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, P. R. China;

²Advanced Research Institute of Multidisciplinary Science, School of Life Science; School of Medical Technology; Key Laboratory of Molecular Medicine and Biotherapy; Key Laboratory of Medical Molecule Science and Pharmaceuticals Engineering; Beijing Institute of Technology, Beijing, 100081, P. R. China.

³State Key Laboratory of Respiratory Disease and School of Basic Medicine, Guangzhou Medical University, Guangzhou 510260, P. R. China

⁴National Laboratory of Biomedicine at Guangzhou, Guangzhou 510260, P. R. China

⁵Institute of Biophysics, Chinese Academy of Science, Beijing 100101 P. R. China

⁶Chinese Academy of Sciences (CAS) Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and safety, National Center for Nanoscience and Technology of China, Beijing, 100190, P.R. China

⁷University of Chinese Academy of Sciences, Beijing 100049, P. R. China

⁸Department of Health Sciences, National Natural Science Foundation of China, Beijing 100085, P. R. China

Equal contributions to this work

*email:

liangxj@nanoctr.cn; tjuguoweisheng@126.com; yyhuang@bit.edu.cn

Supplementary table 1. The amount of funding for five major respiratory infectious diseases from funding agencies in 2012-2019 and 2020-2021.

Funding agency	Project	2012-2019 amount (million)	2012-2019 total (million)	2020-2021 amount (million)	2020-2021 total (million)
NSF	Influenza	6234.6 (\$)	33792.6 (\$)	2013 (\$)	58969 (\$)
	Phthisis	12 (\$)		9 (\$)	
	SARS	15944 (\$)		8333 (\$)	
	MERS	11602 (\$)		541 (\$)	
	COVID-19	0		48073 (\$)	
NIH	Influenza	380477 (\$)	469097 (\$)	144247 (\$)	1093769 (\$)
	Phthisis	203 (\$)		5 (\$)	
	SARS	44929 (\$)		391560 (\$)	
	MERS	43488 (\$)		29335 (\$)	
	COVID-19	0		528622 (\$)	
UKRI	Influenza	15116 (£)	17256 (£)	3540 (£)	61629 (£)
	Phthisis	0 (£)		0 (£)	
	SARS	952 (£)		8630 (£)	
	MERS	1188 (£)		359 (£)	
	COVID-19	0 (£)		49100 (£)	
JPSP	Influenza	50306 (¥)	110668 (¥)	44008 (¥)	202422 (¥)
	Phthisis	0 (¥)		0 (¥)	
	SARS	20452 (¥)		26159 (¥)	
	MERS	39910 (¥)		18012 (¥)	
	COVID-19	0 (¥)		114243 (¥)	

SARS, severe acute respiratory syndrome; MERS, Middle East respiratory syndrome; COVID-19, coronavirus disease 2019; NSF, National Science Foundation; NIH, National Institutes of Health; UKRI, United Kingdom Research and Innovation; JPSP, Japan Society for the Promotion of Science.

Search method

The amount of funding for five major respiratory infectious diseases from different funding agencies in 2012-2019 and 2020-2021 was obtained from the websites of NSF, NIH, UKRI and JSPS. Search condition:(theme= influenza) or (theme=phthisis) or (theme= COVID-19) or (theme=SARS) or (theme=MERS) and (year=2012-2019) or (year=2020-2021).

Websites

National Science Foundation (NSF): <https://www.nsf.gov/>

National Institutes of Health (NIH): <https://www.nih.gov/>

United Kingdom Research and Innovation (UKRI): <https://www.ukri.org/>

Japan Society for the Promotion of Science (JSPS): <https://www.ukri.org/>

National Natural Science Foundation of China (NSFC): <https://www.nsf.gov.cn/>